Medication info

Empagliflozin/ Metformin Hydrochloride Tablet 12.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Ajou Pharmaceutical Co., Ltd.
Appearance
A film-coated tablet that is oval-shaped with a convex surface, white with a pink hue.
Packaging
Bottle packaging - 60 tablets/bottle, PTP packaging - 60 tablets/box [(10 tablets/PTP X 6)], PTP packaging - 10 tablets/box [(10 tablets/PTP X 1)]
Approval status
Active

MFDS item code 202302637 · Approved 2023.09.05

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their current doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients: In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Ajou Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
View approved original text

This medication is used in combination with diet and exercise to help control blood sugar in adults with type 2 diabetes through the administration of empagliflozin and metformin. It is particularly suitable for patients whose blood sugar is not adequately controlled, and caution is necessary in patients with cardiovascular diseases regarding the occurrence of cardiovascular events. This medication improves blood sugar management and aids in diabetes treatment.

How to take

Adult dose

The recommended dose is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their current doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients: In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication helps control blood sugar levels. However, there is a risk of a rare side effect known as severe lactic acidosis, so caution is warranted. There may be a risk of hypoglycemia when used in conjunction with other diabetes medications. This medication should not be used in patients with moderate or severe renal impairment, acute kidney problems, or unstable cardiac function. It should be temporarily discontinued before and after undergoing tests that use iodine contrast agents, and restarted only after confirming normal kidney function. It is also prudent to suspend use temporarily during severe infections, trauma, or surgery. It is not recommended for use in pregnant or breastfeeding women. Since this medication can affect kidney function, regular monitoring of kidney function should be conducted before and during treatment. Care should be taken in cases of dehydration or fluid deficiency, and the medication may be discontinued if necessary. When used in conjunction with insulin or sulfonylureas, dosing adjustments may be required to reduce the risk of hypoglycemia. While taking this medication, there may be an increased risk of urinary infections or genital infections, so patients should consult their healthcare provider immediately if symptoms appear. Gastrointestinal disturbances may occur due to metformin, and regular blood tests may be necessary to monitor vitamin B12 levels. Excessive alcohol intake can increase the risk of lactic acidosis, so it should be avoided. This medication can cause serious infections such as perineal necrosis in some patients, so patients should inform their healthcare provider immediately if pain, redness, or swelling occurs in the genital area. Elderly patients or those with impaired renal function should take special care while using this medication and may require dosing adjustments. In the event of an overdose, immediate medical treatment should be sought, and dialysis may be necessary. It is recommended to avoid use in children, as safety and efficacy have not been established.

Side effects

Hypoglycemia, urinary tract infection, genital infection, increased urination, ketoacidosis, lactic acidosis, decreased vitamin B12 absorption, decreased fluid volume, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, abnormal liver function tests, hepatitis, altered taste, itching, rash, hives, erythema, angioedema, dysuria, interstitial nephritis, thirst, increased serum lipids, increased serum creatinine, decreased glomerular filtration rate, vaginismus, vulvitis, balanitis, perineal necrosis, fluid volume loss, increased serum creatinine, decreased glomerular filtration rate, gastrointestinal symptoms (diarrhea, nausea, vomiting), decreased serum vitamin B12 concentration, chronic gastritis, constipation, gastritis, abdominal discomfort, anal incontinence, dry mouth, gastrointestinal disorders, gastroesophageal reflux disease, oral discomfort, salivary gland pain, cerebral infarction, soft tissue inflammation, pneumonia, ankle fracture, epicondylitis, facial bone fracture, musculoskeletal pain, myocardial infarction, pancreatic carcinoma, chronic otitis media, meningitis, acute pyelonephritis, sepsis, subcutaneous abscess, adnexal-ovarian abscess, vestibular neuritis, headache, dizziness, weakness, chest discomfort, chest pain, increased alanine aminotransferase, increased aspartate aminotransferase, ureterolithiasis, acute kidney injury, hematuria, overactive bladder, renal mass, urinary retention, urinary pain, abnormal urination, vulvar pruritus, benign prostatic hyperplasia, atrophic vaginitis, cervicitis, scrotal pain, sexual dysfunction, vaginal discharge, hyperlipidemia, dyslipidemia, vitamin D deficiency, dermal cyst, seborrheic dermatitis, atopic dermatitis, diabetic foot, nummular eczema, heat rash, sebaceous gland hyperplasia, lumbosacral spinal stenosis, myalgia, limb pain, musculoskeletal chest pain, arthralgia, cervical stenosis, fibromyalgia, flank pain, fracture pain, muscle weakness, osteoarthritis, osteoporosis, rotator cuff syndrome, astigmatism, cataract, allergic conjunctivitis, blurred vision, corneal erosion, glaucoma, macular fibrosis, eye discomfort, eye congestion, pathological myopia, retinal detachment, retinal crystals, retinal vein occlusion, serous retinal detachment, eyelid swelling, visual impairment, vitreous floaters, vitreous hemorrhage, epistaxis, asthma, exertional dyspnea, wet cough, allergic rhinitis, residual phlegm, cough, skin laceration, contusion, rib fracture, concussion, corneal abrasion, fall, hand fracture, iliotibial band syndrome, open globe injury, pelvic fracture, road traffic accident, splenic injury, sternum fracture, angina, palpitations, Prinzmetal angina, coronary artery disease, tachycardia, atherosclerosis, deep vein thrombosis, diabetic vascular complications, peripheral artery occlusive disease, anxiety, depression, sleep disorders, acute cholecystitis, autoimmune hepatitis, cholelithiasis, hepatitis, otalgia, position-related dizziness, vertigo, anemia, lymphadenopathy, hypothyroidism, thyroid nodule, unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1°C and 30°C at room temperature to ensure the medication's effectiveness and safety.

Appearance and packaging

Appearance

A film-coated tablet that is oval-shaped with a convex surface, white with a pink hue.

Package unit

Bottle packaging - 60 tablets/bottle, PTP packaging - 60 tablets/box [(10 tablets/PTP X 6)], PTP packaging - 10 tablets/box [(10 tablets/PTP X 1)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.